source
- Biotech firms must align operating models with their unique DNA, not rely on generic SMID templatesThe article points out that two biotech firms with similar head counts, pipelines and growth plans can operate very differently. One may build extensive internal development infrastructure, while t…
- Oura cancels planned IPO citing market uncertainty despite strong demandOura, known for its smart ring, announced it is withdrawing its initial public offering. The company said the decision was driven by ongoing uncertainty in the IPO market, even though it continues…